What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy?
by
Friedman MJ
National Center for PTSD,
VA Medical and Regional Office Center,
White River Junction,
VT 05009-0001, USA
J Clin Psychiatry 2000; 61 Suppl 7:44-51

ABSTRACT

This review considers future directions for developing effective drugs for posttraumatic stress disorder (PTSD). At present, we have embarked upon an empirical approach in which pharmacologic research consists of clinical trials with agents, such as antidepressants, anxiolytics, and anticonvulsants, initially developed for different purposes. The approach taken here is theoretical rather than empirical, starting with what is known about the unique pathophysiology of PTSD and then predicting the types of pharmacologic agents that might prove effective in the future. Such classes of compounds include corticotropin-releasing factor antagonists, neuropeptide Y enhancers, antiadrenergic compounds, drugs to down-regulate glucocorticoid receptors, more specific serotonergic agents, agents normalizing opioid function, substance P antagonists, N-methyl-D-aspartate facilitators, and antikindling/antisensitization anticonvulsants.

PTSD
NMDA
SSRIs
NARIs
RIMAs
1990s
Options
Ketamine
Antisense
SSRIs/SNRIs
Comparisons
Neurotrophins
New anxiolytics
Antidepressants
Vagus stimulation
New antipsychotics
Fluoxetine and PTSD
New antidepressants
Neurokinins/Substance P
SNaRIs, NaSSAs, and NaRIs
PTSD: SSRIs versus Non-SSRIs
Mood enhancement via stem cell therapy
The neurotrophic effects of antidepressants
Pharmacogenomics and new antidepressants

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
Utopian Pharmacology
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family